Meet our team at Phacilitate Advanced Therapies Week US: Jan. 16-19, 2024 in Miami, FL.
The event
The US Phacilitate Advanced Therapies Week conference will take place January 16-19 2024 at the Miami Beach Convention Center in Miami, Florida.
Stop by our booth #612 to meet our team during the Phacilitate Advanced Therapies week US and learn more about our extended services to bring your cell and gene therapies to life… SK pharmteco is assembling the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, end-to-end, best-in-class services from pre-clinical through commercial, including:
- Process development
- Plasmid DNA
- Vector manufacturing
- Cell banking
- Cell processing
- A full suite of complementary and standalone testing and analytical capabilities.
Learn more about our newly launched Viral Vector Manufacturing Platforms: LentiSure™ and AAVelocity™!
In 2023, SK pharmteco launched two viral vector manufacturing platforms to ensure a cost and time-effective manufacturing. Our platforms are Plug-and-Play, Robust and Proven, stop by our booth to learn more!
Presentation
On January 18, our expert John Lee, Global Head of Cell and Gene Therapy will make a presentation during the Advanced therapies week:
Cell and Gene Therapy in 2024 – No Regrets Strategies for Either Feast or Famine
- How macro trends (e.g., 2030 patent cliff, CMS drug pricing negotiations) will impact CGT
- Which funding, M&A, or clinical milestones are leading indicators for industry performance
- What key facility/technology, process, and personnel investments yield ROI at the lowest risk in both bull and bear markets
Presented during the “How Robust is the Cell & Gene Therapies Industry? Investment Funding and Commercial Returns” session and followed by a panel discussion.
Date: Thursday, January 18, 2024
Time: 3:00 PM to 4:00 PM.
Location: Commercializing Future Therapies, Theatre 5.
Participants:
- Peter Olagunju, Board of Directors, March Biosciences
- Gregory Fiore, Former Chief Executive Officer, Exacis Biotherapeutics
- Stefanos Theoharis, Venture Partner and Sector Scoping Committee Member, Deep Science Ventures